NCT00358826 - Study Effect of VIA-2291 on Vascular Inflammation | Biotech Hunter

Enrollment

191

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

September 30, 2008

Conditions

Coronary Artery Disease

Interventions

DRUG

VIA-2291

oral dosing, 1 time daily for 12 or 24 weeks

DRUG

Placebo

oral dosing, 1 time daily for 12 or 24 weeks

Trial Locations (12)

27401

LeBauer Cardiovascular Research Foundation, Greensboro

32901

MIMA Century Research Associates, Melbourne

38801

Cardiology Associates Research, LLC, Tupelo

55407

Minneapolis Heart Institute, Minneapolis

77901

Victoria Heart and Vascular Center, Victoria

T2N 2T9

Foothills Medical Center, Calgary

V8R 4R2

Victoria Heart Institute Foundation, Victoria

B3H 3A7

Queen Elizabeth II HSC, Halifax

H1T 1C8

Montreal Heart Institute, Montreal

H2L 4M1

Notre Dame Hospital, Montreal

H4J 1C5

Hospital Sacre-Coeur, Montreal

J6E 6J2

Constituante Centre Hospitalier Regional De Lanaudiere, Saint-Charles-Borromée

All Listed Sponsors

collaborator

Montreal Heart Institute

OTHER

lead

Tallikut Pharmaceuticals, Inc.

INDUSTRY